{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.6","upperLimit":"47.2","value":"40.3"},{"groupId":"OG001","lowerLimit":"23.1","upperLimit":"42.6","value":"32.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"A secondary endpoint is the ORR for the Treatment Part of the study. ORR is defined as the percentage of patients with a confirmed CR (complete response) or PR (partial response) by RECIST v1.1. The confirmed response is defined as a CR or PR on subsequent tumor assessment at least 28 days after first response documentation. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to the rucaparib arm.","id":"OG000","title":"Rucaparib"},{"description":"Patients randomized to the chemotherapy arm.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Efficacy population with measurable disease at baseline. Efficacy population defined as all randomized patients with a deleterious BRCA mutation, excluding those identified to have a BRCA reversion mutation.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.","title":"Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (Efficacy Population)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}